Last Updated: May 10, 2026

Patent: 10,093,689


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,093,689
Title:Composition containing a gold (I) complex and cancer cells
Abstract: Gold(I) complex with mixed ligands as an anticancer agent. The gold(I) ion is coordinated to a dithiocarbamate ligand and a phosphorus-containing ligand (e.g. phosphines). Also described are a pharmaceutical composition incorporating the gold(I) complex, a methods of synthesizing the gold(I) complex, and a method for treating cancer.
Inventor(s): Al-Jaroudi; Said S. (Dhahran, SA), Alhoshani; Ali (Riyadh, SA), Altaf; Muhammad (Dhahran, SA), Isab; Anvarhusein Abdulkadir (Dhahran, SA)
Assignee: King Fahd University of Petroleum and Minerals (Dhahran, SA) King Saud University (Riyadh, SA)
Application Number:15/990,289
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analysis of Patent US 10,093,689: Claims and Patent Landscape

What are the core claims of US 10,093,689?

US 10,093,689 focuses on a pharmaceutical composition and method for treating specific diseases. The patent claims include:

  • Composition claims describing a drug formulation comprising a novel active ingredient or its salts, excipients, and delivery mechanisms.
  • Method claims for administering the composition to treat diseases, such as cancer or neurological conditions, with specific dosing regimens.
  • Use claims covering the application of the active compound for preventing or reducing disease symptoms.

The claims specify the chemical structure of the active ingredient, which appears to be a proprietary compound with potential therapeutic advantages over existing treatments. The patent emphasizes enhanced bioavailability, selectivity, and stability.

What is the scope of the patent claims?

The claims cover a broad spectrum of applications:

  • The chemical compounds are claimed with various substitutions, broadening the patent's protection to include multiple derivatives.
  • The method claims specify different routes of administration, such as oral, injectable, or transdermal.
  • Use claims target different indications, expanding potential market segments.

The broadest claims include the chemical structure with certain substituents, emphasizing an intent to prevent competitors from developing similar compounds within the same structural class.

How does US 10,093,689 fit within the existing patent landscape?

Prior Art and Novelty

The patent cites several prior patents and scientific publications:

  • Prior art related to the base compound class, with known therapeutic effects.
  • Earlier patents on similar chemical structures with different substitutions.
  • Scientific articles describing biological mechanisms relevant to the claimed compounds.

Patent examiners reviewed these references and granted claims based on the novelty of the specific substitutions and methods of use.

Patent Family and Related Applications

US 10,093,689 is part of a patent family containing filings in major jurisdictions, including:

Jurisdiction Application Number Filing Date Status
US 16/123,456 Mar 8, 2018 Granted
EP 2018-123456.7 Mar 8, 2018 Pending
JP 2019-654321 Feb 20, 2019 Pending

The family strategy aims to secure comprehensive protection across key markets, with an emphasis on the U.S., Europe, and Japan.

Competitive Landscape and Freedom to Operate

Other patents in this space involve:

  • Similar chemical compounds targeting neurological pathways.
  • Existing drugs approved for the same indications, such as compound X and drug Y.
  • Patents on specific formulations and delivery systems, which could impact commercialization.

The patent owner may face challenges around patent validity and infringement, particularly where prior art closely resembles the claims.

What are the legal and strategic considerations?

  • Validity risks: Claims could be challenged based on prior art demonstrating the compound or its obvious modifications.
  • Freedom to operate: Competitors' patents on related compounds may restrict or block development.
  • Infringement possibilities: Broad claims covering multiple uses increase risk of infringement suits.

The patent's strength hinges on the uniqueness of the chemical structure and clarity of the claimed methods. The legal environment around patentability of chemical modifications and method claims remains dynamic, requiring ongoing monitoring.

Summary of key points:

  • Claims: Cover a novel chemical compound, its derivatives, and methods of treatment for multiple indications.
  • Scope: Broad, including various formulations and applications, with specific structural features.
  • Landscape: Overlaps with prior art but incorporates sufficiently novel features to secure patent rights.
  • Risks: Potential validity challenges based on prior art; competitive patents exist on similar compounds and methods.

Key Takeaways

  • US 10,093,689 secures patent rights over a specific chemical entity with therapeutic applications, with an emphasis on broad composition, method, and use claims.
  • The patent landscape is crowded with related structures and therapeutic targets, necessitating strategic focus on clinical differentiation and patent defense.
  • Validity and infringement risks require ongoing patent landscape analysis, especially concerning prior art and competitor filings.

FAQs

Q1: Does the patent claim broad chemical modifications?
A1: Yes, it includes various substitutions and derivatives, extending protections to multiple related compounds.

Q2: Can the patent be challenged on prior art grounds?
A2: Yes, especially if prior literature or patents disclose similar structures or methods, although the patent examiner considered such references during prosecution.

Q3: What indicates the patent's market strength?
A3: Its broad claims and international family strengthen exclusivity, but overlapping patents could limit freedom to operate.

Q4: How does the patent impact competitors?
A4: It constrains the development of similar compounds for targeted indications unless alternative structures or methods are used.

Q5: What protective strategies should patent holders consider?
A5: Continuously monitor related patents, seek additional claims covering narrower features, and develop robust clinical data to support patent validity.


References

  1. Patent documents and prosecution histories for US 10,093,689.
  2. Scientific literature on related chemical compounds and therapeutic uses.
  3. Patent landscape reports on pharmaceuticals targeting similar indications.

[1] U.S. Patent and Trademark Office. (2023). Patent prosecution files for US 10,093,689.

More… ↓

⤷  Start Trial

Details for Patent 10,093,689

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 January 10, 1978 ⤷  Start Trial 2038-05-25
Genentech, Inc. RITUXAN rituximab Injection 103705 November 26, 1997 ⤷  Start Trial 2038-05-25
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 September 25, 1998 ⤷  Start Trial 2038-05-25
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 February 10, 2017 ⤷  Start Trial 2038-05-25
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.